

Fetal liver hepcidin secures iron stores in utero

Lara Kämmerer^{1*}, Goran Mohammad^{1*}, Magda Wolna^{1*}, Peter A. Robbins¹, Samira Lakhal-Littleton¹✉

¹ Department of Physiology, Anatomy and Genetics, University of Oxford. Parks Road, Oxford OX1 3PT

*These authors contributed equally to this work.


Correspondence should be addressed to Samira Lakhal-Littleton, Department of Physiology, Anatomy and Genetics, University of Oxford. Parks Road, Oxford OX1 3PT, email samira.lakhal-littleton@dpag.ox.ac.uk

Running title- Fetal liver hepcidin secures fetal iron stores

Key Points

1. Fetal liver hepcidin operates cell-autonomously to enable rapid build-up of fetal liver iron stores in the third trimester of gestation.
2. Placental ferroportin is not regulated by fetal hepcidin under normal physiological conditions.

Visual Abstract



Abstract

In the adult, the liver-derived hormone hepcidin (HAMP) controls systemic iron levels by blocking the iron-exporting protein ferroportin (FPN) in the gut and spleen, the sites of iron absorption and recycling respectively. Impaired HAMP expression or FPN responsiveness to HAMP result in iron overload. HAMP is also expressed in the fetal liver but its role in controlling fetal iron stores is not understood. To address this question in a manner that safeguards against the confounding effects of altered maternal iron homeostasis, we generated fetuses harbouring a paternally-inherited ubiquitous knock-in of the HAMP-resistant *fpn*C326Y. Additionally, to safeguard against any confounding effects of altered placental iron homeostasis, we generated fetuses with a liver-specific knock-in of *fpn*C326Y or knockout of the *hamp* gene. These fetuses had reduced liver iron stores and hemoglobin, and markedly increased FPN in the liver, but not in the placenta. Thus, fetal liver HAMP operates cell-autonomously to increase fetal liver iron stores. Our findings also suggest that FPN in the placenta is not actively regulated by fetal liver HAMP under normal physiological conditions.

Keywords

Hepcidin

Ferroportin

Iron stores

Fetal liver

Placenta

Text word count- 4200

Abstract word count- 174

Number of figures- 4

Introduction

Iron is essential for growth and development. Suboptimal iron availability at birth is associated with cognitive, behavioural and motor skill deficits, and increased risk of developing anaemia in infancy (1-7). Some of these developmental deficits are not reversible by oral iron therapy in the neonate (8-15). In the first 6-9 months of age, the neonate is not fully competent in regulating dietary iron absorption in response to iron needs (16,17), and depends on liver iron stores to support its growth and development (18,19).

In the adult, the liver-derived hormone HAMP controls systemic iron availability, which in turn controls liver iron stores (20, 21). HAMP operates by blocking the iron export protein ferroportin (FPN) in the gut and the spleen, the sites of iron absorption and recycling respectively (20,21). Disruption of the HAMP/FPN axis, in a manner that reduces HAMP levels or FPN responsiveness to HAMP, leads to the iron-overload disease hemochromatosis. This is characterised by increased serum iron concentration, depletion of iron from the spleen and excess deposition in the liver (22). The hemochromatosis phenotype is recapitulated in adult mice harbouring ubiquitous knock-in of the HAMP-resistant *fpnC326Y* allele, or liver-specific knockout of the *hamp* gene (23, 24).

HAMP expression has also been detected in the fetal liver (25). In contrast to adult HAMP, the role of fetal HAMP in determining liver iron stores in utero is not entirely understood. One study reported that endogenous HAMP was not expressed in the mouse fetal liver but that transgenic ubiquitous overexpression of the *hamp* gene resulted in anaemic fetuses (26). Another study found that ubiquitous homozygous loss of the *matriptase-2* gene in fetuses (*matriptase-2* is a negative regulator of *hamp* expression) resulted in reduced body non-heme iron levels (27). A third study comparing fetuses harbouring a homozygous deletion of the hemochromatosis gene *hfe* (*HFE* is a protein that is necessary for *hamp* expression), with wild type littermates did not find any difference in total liver iron stores, but reported higher levels of non-heme iron in *hfe*-ko fetuses when mothers were fed an iron-rich diet. (28). Based on these studies, it has been hypothesised that fetal liver HAMP controls iron availability to the fetus by blocking FPN-mediated iron transport into the fetal capillaries of the placental syncytiotrophoblast (STB) (29). However, a more recent study found that ubiquitous deletion of the *hamp* gene did not affect fetal liver iron stores under either iron-replete or iron-deficient conditions (30).

A common feature of the above studies is that the genetic variants in the fetuses were also present in the fetal part of the placenta, in the mother, and in the maternal part of the placenta. We sought to interrogate the role of fetal liver HAMP without these potentially confounding effects. To avoid those associated with altered iron control in the mother or

maternal side of the placenta, we generated fetuses harbouring a paternally-inherited ubiquitous knock-in of the HAMP-resistant *fpnC326Y* allele. To avoid the additional potentially confounding effects of altered iron control in the fetal part of the placenta, we also generated fetuses harbouring a liver-specific knock-in of the HAMP-resistant *fpnC326Y* allele, or liver-specific knockout of the *hamp* gene, through paternal inheritance of the hepatocyte-specific Albumin-Cre recombinase transgene. For these models, we then compared the levels of liver iron stores and haemoglobin between the affected fetuses and their littermate controls.

Methods

Mice

All animal procedures were compliant with the UK Home Office Animals (Scientific Procedures) Act 1986 and approved by the University of Oxford Medical Sciences Division Ethical Review Committee. The conditional *fpnC326Y^{fl}* allele was generated as described previously (23). Females were time-mated between 9 and 12 weeks of age and fetuses were harvested from first pregnancies.

Fetal tissue

Fetal tissues were harvested from PBS-perfused mothers at e13.5 or e17.5, washed further in PBS then either snap-frozen for RNA and iron measurement studies or fixed in formalin for histological studies. Fetal blood was collected at e17.5 by decapitation.

Immunostaining

Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with rabbit polyclonal anti-mouse FPN antibody (NBP1-21502, Novus biologicals) at 1/200 dilution. Alexa 488-conjugated anti-rabbit antibody (ab150073, Abcam) was then used as a secondary antibody at a dilution of 1/500.

Iron indices

Determination of total elemental iron in tissues from PBS-perfused animals was carried out by inductively coupled plasma mass spectrometry (ICP-MS) as described previously (23). Concentrations were normalised to wet weight. Haemoglobin was recorded from fresh blood using the HemoCue Hb 201+ system. DAB-enhanced Perls' iron stain was carried out in FFPE sections as described previously (23).

Diet provision during pregnancy

Unless otherwise stated, mothers were fed a standard chow diet containing 200ppm iron. In iron-loading studies, mothers were fed a diet containing 5000ppm iron (Teklad TD.140464) as soon as mated. In iron-deficient studies, mothers were fed a diet containing 5ppm iron (Teklad TD.99397) from weaning and throughout pregnancy.

Western blotting

Tissues were snap-frozen in liquid nitrogen, crushed then lysed using RIPA Lysis Buffer System (Santa Cruz sc-24948), according to the manufacturer's instructions. Tissue lysates were cleared by centrifugation at 15000g for 10 min at 4C. Protein concentration in the lysates was measured by BCA Protein Assay (Pierce 23225) and normalised to the same concentration for each batch. Lysates were then diluted in non-reducing Laemmli SDS sample buffer and heated at 95C for 5min. 30 to 50ug of protein were loaded onto Mini-PROTEAN TGX Gels (Biorad, 4561096). After electrophoresis, protein was transferred onto cellulose membrane using the BioRad Translotter system, and membranes were blocked for an hour in blocking buffer containing 5% bovine serum albumin. Membranes were then stained overnight at 4C with rabbit polyclonal anti-mouse FPN antibody (NBP1-21502, Novus biologicals) at 1/1000 or HRP-conjugated anti beta Actin antibody (Proteintech HRP-60008) at 1/5000. Blots were developed using the ECL prime detection kit (RPN2232, VWR International). Signal intensities were quantified by ImageJ, and the ratio between the FPN and the beta-Actin signals calculated to produce normalised intensities.

Erythroid progenitors in fetal livers

Quantitation of erythroid progenitors in fetal livers was performed according to a previously published method (31). Following harvest, fetal livers were dissociated in ice-cold PBS containing 3% FCS, then immediately co-stained with FITC-conjugated rat anti-mouse cluster of differentiation CD71 antibody (BD Biosciences 553266) and PE-conjugated rat anti-mouse TER-119 antibody(553673 BD Biosciences), both diluted at 1/1000. Cells were washed three times then subject to flow cytometry using the BDX20 system (BD Biosciences). Dot blot analysis was performed using FlowJo.

Gene expression

Gene expression was assessed by quantitative real-time PCR, using Applied Biosystems Taqman gene expression assay probes for fpn, tfr1, dmt1, hamp and house-keeping gene β -Actin (Life Technologies, *Carlsbad, CA*). The CT value for the gene of interest was first normalised by deducting the CT value for β -Actin to obtain a delta CT value. Delta CT values of test samples were further normalised to the average of the delta CT values for control samples to obtain delta delta CT values. Relative gene expression levels were then calculated as $2^{-\text{delta delta CT}}$.

Statistics

Values are shown as mean \pm standard error of the mean (S.E.M). Paired comparisons were performed using Student's T test. Multiple comparisons were drawn using ANOVA. Post hoc tests used the Bonferroni correction. R values reported are Pearson correlation coefficients.

Results

Fetal liver iron concentration and hepcidin expression increase in the third trimester

In the mouse, the fetal liver forms in the second half of gestation. We found that the total concentration of elemental iron in the fetal liver increased by 2.75 fold between e13.5 and e17.5, to levels well above those in the maternal liver at e17.5 (and similar to those in non-pregnant females), consistent with increased liver iron stores (Figure 1A). Over the same period of time, fetal liver hamp mRNA expression increased by 24 fold (Figure 1B).

Nevertheless, at e17.5, fetal liver hamp mRNA expression was \sim 18 fold lower than that of maternal liver hamp (Figure 1B). There was a positive correlation between the concentration of iron and the expression of hamp mRNA in the fetal liver at e.17.5 (Figure 1C).

Ubiquitous loss of FPN responsiveness to hepcidin reduces fetal liver iron stores and haemoglobin

To probe the role of fetal HAMP in regulating fetal liver iron stores, we used mice harbouring a ubiquitous knock-in of a HAMP-resistant FPN. To guard against a confounding effect of maternal iron overload, we set up matings using wild type *fpn*^{wt/wt} mothers and *fpn*^{wt/C326Y} fathers heterozygous for the knock-in mutation of *fpn*C326Y, an isoform of FPN with intact iron export function but which is resistant to HAMP-mediated degradation. At e17.5 *fpn*^{wt/C326Y} fetuses had lower fetal liver iron concentration compared with *fpn*^{wt/wt} littermate controls (Figure 2A). DAB-enhanced Perls stain demonstrated iron staining in periportal hepatocytes in *fpn*^{wt/wt} livers that was absent in *fpn*^{wt/C326Y} livers (Figure 2B). The difference in liver iron stores between e17.5 *fpn*^{wt/C326Y} fetuses and littermate controls disappeared within the first week of life (Figure 2A). As expected, by 12 weeks of age, *fpn*^{wt/C326Y} mice had liver iron concentrations that were higher than those of *fpn*^{wt/wt} littermate controls, consistent with the hemochromatosis phenotype reported in our previous studies (23). Extrahepatic iron concentration at e17.5 (measured in the carcass) was also reduced in *fpn*^{wt/C326Y} mice compared with *fpn*^{wt/wt} littermates, consistent with the ubiquitous expression of the *fpn*^{C326Y} allele (Figure 2C). Extrahepatic iron concentration (measured as splenic iron) was comparable between mice of the two genotypes at birth (d0), and at 1 and 4 weeks of age, but lower in *fpn*^{wt/C326Y} mice than in *fpn*^{wt/wt} littermate controls at 12 weeks of age, consistent with the development of hemochromatosis at this later stage (Figure 2C) (23). Hemoglobin

levels at e17.5 and birth (d0) were lower in *fpn^{wt/C326Y}* mice than in *fpn^{wt/wt}* littermate controls (Figure 2D), although this difference disappeared by one week of age (Figure 2D). This finding suggests that limited fetal liver iron stores affect fetal haematopoiesis. In late gestation, the liver becomes a site of hematopoiesis, with erythroid progenitor cells transitioning through 5 stages of differentiation (R1 through to R5) (31). We found that hemoglobin levels at e17.5 correlated most positively with the percentage of terminally differentiated cells (R5) and most negatively with the percentage of intermediate cells (R3) (Supplemental Figure 1A, B). Importantly, reduced iron stores in *fpn^{wt/C326Y}* fetuses were associated with lower percentage of R5 cells in their livers compared to livers of *fpn^{wt/wt}* littermate controls (Figure 2E, 2F). These results confirm that reduced liver iron stores limit the later stages of erythroid differentiation in the fetal liver.

Having observed that ubiquitous loss of FPN responsiveness to hepcidin in fetal tissues resulted in reduced fetal liver iron stores and lower haemoglobin levels, we sought to determine whether these effects could be attributed to changes in iron transfer across the placenta. However, we found that placental iron concentration (Figure 2G), placental expression of iron-regulated transcripts transferrin receptor 1 (*tfr1*) and divalent metal transporter (*dmt1*) (Figure 2H), and the concentration of iron in fetal serum (Figure 2I) were all comparable between *fpn^{wt/C326Y}* mice and *fpn^{wt/wt}* littermates, suggesting that placental iron flux is not different between animals of the two genotypes. Additionally, FPN levels were not different between placentae of *fpn^{wt/C326Y}* mice and placentae of *fpn^{wt/wt}* littermates (Figure 2J-K), indicating that FPN at this site is not actively regulated by hepcidin in the iron-replete state. To explore whether placental FPN was regulated by hepcidin in the setting of iron overload, we provided *fpn^{wt/wt}* mothers carrying *fpn^{wt/wt}* litters with iron-loaded diet containing 5000ppm iron. Provision of iron-loaded diet raised the concentration of iron and the expression of hepcidin in the fetal and maternal livers and in the placenta itself (Supplemental Figure 2A, B). FPN was decreased in the fetal liver but increased in the placenta in response to the iron-loaded diet (Supplemental Figure 2C-F). Consistent with this increase in placental FPN, the concentration of iron in the fetal serum was also raised by the iron-loaded diet (Supplemental Figure 2G). These data further confirm that fetal liver but not placental FPN is subject to regulation by HAMP.

Apart from the placenta, the other major site of FPN expression is the fetal liver itself. Therefore, we examined whether FPN expression in the livers of *fpn^{wt/C326Y}* fetuses was altered, and found that it was markedly increased compared to livers of *fpn^{wt/wt}* littermates at e17.5 (Figure 2L, M). Therefore, we hypothesised that this marked increase in FPN expression is the cause of decreased fetal liver iron stores seen in *fpn^{wt/C326Y}* fetuses.

Liver-specific loss of FPN responsiveness to hepcidin reduces fetal liver iron stores and hemoglobin

To test the hypothesis that increased FPN in the fetal liver leads to a reduction in iron stores, we generated fetuses harbouring a liver-specific knock-in of the *fpnC326Y* allele, by mating *fpnC326Y^{fl/fl}* mothers with *fpnC326Y^{fl/fl}* fathers transgenic for Cre recombinase driven by the hepatocyte-specific albumin promoter (*fpnC326Y^{fl/fl}*, Alb.Cre+). Liver iron concentration in *fpnC326Y^{fl/fl}*, Alb.Cre+ livers at e17.5 and at birth was reduced relative to *fpnC326Y^{fl/fl}* littermates (Figure 3A). This was confirmed histologically by DAB-enhanced Perls' iron stain (Figure 3B). Interestingly, at 12 weeks of age, *fpnC326Y^{fl/fl}*, Alb.Cre+ mice had a reduction in liver iron concentration suggesting a possible autocrine role for HAMP in regulating liver iron stores in the adult (Figure 3A). Unlike *fpn^{wt/C326Y}* mice, extrahepatic iron concentration at e17.5 (measured in the carcass) and at later stages (measured as splenic iron) were not reduced in *fpnC326Y^{fl/fl}*, Alb.Cre+ mice relative to the respective controls. This confirms that iron loss in this setting is limited to the liver, in line with the specificity conferred by the Alb.Cre+ transgene (Figure 3C). *fpnC326Y^{fl/fl}*, Alb.Cre+ fetuses had lower hemoglobin levels at e17.5, although this recovered to control levels in the first week of life (Figure 3D). Lower hemoglobin levels at e17.5 were also associated with a reduction in the percentage of terminally differentiated erythroblasts in the fetal liver (Figure 3E, F). The findings that hemoglobin levels and erythroid differentiation were reduced even when loss of HAMP-responsiveness was confined to hepatocytes is consistent with a direct role for hepatocytes iron stores *per se* in supporting hematopoiesis in the fetal liver. The reduction in fetal liver iron concentration could not be attributed to changes in placental iron flux, because placental iron concentration (Figure 3G), placental expression of iron-regulated transcripts *tfr1* and *dmt1* (Figure 3H) and iron concentration in the fetal serum (Figure 3I) were not different between *fpnC326Y^{fl/fl}*, Alb.Cre+ animals and their littermate controls. Consistent with this, placental FPN protein levels were similar between animals of the two genotypes (Figure 3J, K). In contrast, hepatic FPN expression was higher in *fpnC326Y^{fl/fl}*, Alb.Cre+ fetuses than in *fpnC326Y^{fl/fl}* littermates at e17.5 (Figure 3L, M). These results confirm that FPN in fetal hepatocytes is subject to regulation by HAMP and that this regulation is important for the control of fetal liver iron stores.

Fetal liver hepcidin regulates fetal liver FPN and iron stores

Next, we set out to identify the source of HAMP that regulates fetal liver FPN and consequently the liver's iron stores. The previous observations that fetal liver *hamp* mRNA increased 24 fold between e13.5 and e17.5 and that it correlated positively with fetal liver iron stores (Figure 1B, D) suggest that the fetal liver is the source of HAMP that regulates

fetal liver FPN and iron concentration. To test this hypothesis, we deleted the *hamp* gene specifically in the fetal liver by mating *hamp*^{fl/fl} mothers with *hamp*^{fl/fl}, Alb.Cre+ fathers. We found that at e17.5, *hamp* mRNA expression was reduced by 80% in the livers of *hamp*^{fl/fl}, Alb.Cre+ fetuses relative to *hamp*^{fl/fl} littermates, confirming the activity of the Cre allele at this gestational stage (Supplemental Figure 3A). Loss of fetal liver HAMP resulted in decreased fetal liver iron concentration compared with *hamp*^{fl/fl} littermates (Figure 4A), and this was further confirmed histologically by DAB-enhanced Perls' iron stain (Figure 4B). The difference in liver iron stores between *hamp*^{fl/fl}, Alb.Cre+ fetuses and *hamp*^{fl/fl} littermates disappeared within the first week of life, with mice of both genotypes having comparable liver iron stores at 1 and 4 weeks of age (Figure 4A). As expected, 12 week old *hamp*^{fl/fl}, Alb.Cre+ mice had markedly increased liver iron concentrations consistent with the well-recognised role for hepatic HAMP in controlling liver iron stores in the adult (Figure 4A). Extrahepatic iron concentration at e17.5 (measured in the carcass) was not different between *hamp*^{fl/fl}, Alb.Cre+ fetuses and *hamp*^{fl/fl} littermates, consistent with the notion that fetal liver HAMP regulates liver iron primarily in an autocrine manner (Figure 4C). In contrast, extrahepatic iron concentration (measured as splenic iron) was markedly reduced in 12 week old *hamp*^{fl/fl}, Alb.Cre+mice, consistent with the re-distribution of iron from the spleen to the liver (Figure 4C). *hamp*^{fl/fl}, Alb.Cre+ fetuses also had reduced hemoglobin levels at e17.5 (Figure 4D), associated with a reduction in the percentage of late differentiation stages R4 and R5 erythroid cells in the fetal liver (Figure 4E, F). The reduction in fetal liver iron stores could not be attributed to changes in placental iron flux, as placental iron concentration (Figure 4G), placental expression of iron-regulated transcripts *tfr1* and *dmt1* (Figure 4H) and the concentration of iron in the fetal serum (Figure 4I) were not different between *hamp*^{fl/fl}, Alb.Cre+ fetuses and their *hamp*^{fl/fl} littermate controls. Consistent with this, placental FPN protein levels were comparable between animals of the two genotypes (Figure 4J, K). In contrast, FPN levels were markedly increased in the livers of *hamp*^{fl/fl}, Alb.Cre+ fetuses compared to littermate controls (Figure 4L, M).

These results demonstrate that fetal liver HAMP operates to control fetal liver iron stores in the iron replete setting. Interestingly, fetal liver HAMP does not appear to protect fetal liver iron stores in the setting of iron deficiency. Indeed, both *hamp*^{fl/fl}, Alb.Cre+ fetuses and their *hamp*^{fl/fl} littermates became severely iron-depleted when mothers were fed an iron-deficient diet from weaning and throughout pregnancy (Supplemental Figure 3B). Consistent with this, provision of an iron-deficient diet to the mother did not affect the expression of hepcidin in the fetal liver (Supplemental Figure 4A), despite causing a marked reduction in fetal liver iron stores (Supplemental Figure 4B).

Discussion

The importance of liver iron stores for neonatal growth is well recognized (1-7). As demonstrated in the present study, these stores also support hematopoiesis in the fetal liver. To ensure adequate liver iron endowment in late gestation and at birth, there is a need for a rapid build-up of iron levels within fetal hepatocytes.

The first important finding from this study is that fetal liver HAMP operates in a cell-autonomous manner to facilitate the build-up of fetal liver iron stores. The findings that fetal liver HAMP expression is significantly lower than that of maternal liver HAMP, and that loss of fetal liver HAMP does not affect extrahepatic iron levels, are consistent with an autocrine rather than endocrine mode of action. This autocrine mode of action is further supported by the findings of a previous study, in which raised HAMP in the livers of neonates with early-onset neonatal sepsis (EONS) were associated with decreased FPN and increased iron sequestration in the fetal liver (32). In the present study, we found that ubiquitous, but not liver-specific, loss of HAMP responsiveness was associated with a transient decrease in extrahepatic iron in fetuses. This finding suggests that iron levels in other fetal tissues may well be subject to regulation by non-hepatic HAMP.

The second important finding from the present study is that fetal liver HAMP does not exert endocrine effects on FPN in the placenta under normal physiological conditions. In the setting of early-onset neonatal sepsis, it has been reported that cord blood HAMP levels are raised and associated with decreased FPN levels in the placenta (32). However, maternal HAMP is also known to be raised in inflammatory conditions, and cross-contamination of cord blood with maternal blood is a well-documented phenomenon that cannot be excluded (33-36). Nonetheless, it would be important to determine if, under certain pathological conditions, fetal liver HAMP levels are sufficiently raised to exert endocrine effects on the placenta.

The role of fetal liver HAMP has been explored before. One study reported that transgenic ubiquitous overexpression of the *hamp* gene resulted in anaemic fetuses (26). Another study found that ubiquitous homozygous loss of the *matriptase-2* gene in fetuses resulted in reduced body non-heme iron levels (27). A third study using fetuses harbouring a homozygous deletion of the hemochromatosis gene *hfe* did not find any difference in total liver iron stores, but reported higher levels of non-heme iron in *hfe*-ko fetuses when mothers were fed an iron-rich diet (28). A more recent study found that ubiquitous deletion of the *hamp* gene did not affect fetal liver iron stores either under iron-replete or under iron-deficient conditions (30). Along with the present study, these studies diverge from one another in terms of the conclusions drawn as to the importance of fetal liver HAMP. However, there are two very important aspects within the experimental approaches that may

underlie this divergence. First, when the deletion of the *hamp*, *matriptase-2* or *hfe* genes is present throughout all stages of pregnancy, it can potentially affect FPN in early gestation, before the placenta has been formed. Indeed, before it is ever expressed in the placenta, FPN is present in the visceral endoderm and yolk sac, where it plays a non-redundant role in iron supply to the fetus (explaining why *fpn* null embryos are lethal by e7.5) (37, 38). In the present study, the use of the Alb-Cre transgene means that fetal liver HAMP or HAMP responsiveness is only removed once the Albumin promoter becomes activated in the developing liver. Second, when the deletion of the *hamp*, *matriptase-2* or *hfe* genes is achieved through maternal inheritance, it will also alter iron homeostasis in the mother and in the placenta. In this context, both maternal iron status and placental iron homeostasis are known to be important determinants of fetal liver iron stores (28, 30). These potentially confounding factors have been eliminated in the present study by the use of paternally inherited alleles. Nonetheless, the divergent outcomes of these studies indicate the complexity of the role of the HAMP/FPN axis in pregnancy, which involves HAMP from potentially three different sources, pre and post-placental functions of FPN, and the modifying effects of maternal and placental iron homeostasis. Another interesting observation is that, under conditions of early and sustained iron deficiency (as with the provision of iron-deficient diet to the mothers throughout pregnancy), fetal liver iron stores are reduced to a similar extent regardless of the presence or absence of fetal liver HAMP. This apparent lack of modifying effect by HAMP is most likely explained by the profound suppression of the *fpn* transcript which we observed in this setting (Supplemental Figure C), with the implication that the levels of fetal liver HAMP are of little consequence in the absence of FPN. Under conditions of limited iron availability, Iron-Regulatory Proteins (IRPs) act to reduce FPN levels, normally through translational rather than transcriptional suppression (40). Therefore, it will be important, in the future, to identify the mechanisms mediating suppression of *fpn* transcript by iron deficiency and to determine if these mechanisms protect fetal liver iron stores in the setting of severe iron deficiency. The present study raises further questions as to the role of IRPs in regulating fetal liver iron stores. Indeed, despite a reduction in liver iron concentration, the expression of iron-regulated genes *tfr1* and *dmt1* were not raised in the livers of *fpn*^{wt/C326Y} *hamp*^{fl/fl}, Alb.Cre+ mice and *fpn*^{C326Y} *hamp*^{fl/fl}, Alb.Cre+ fetuses compared to their respective littermate controls (Supplemental Figure 4D,E, F). Additionally, provision of iron-deficient diet which produced an even more profound reduction in fetal liver iron concentration (Supplemental Figure 4B), failed to change the expression of *tfr1* and *dmt1* in fetal livers (Supplemental Figure 4G, H), while markedly increasing them in the placenta (Supplemental Figure 4G-H). These findings are consistent with a recent study reporting that IRP1 in the placenta is important for regulating placental iron homeostasis (30). In that study, IRP1 -/- fetuses did not differ from IRP1+/+ fetuses in terms of liver iron concentration,

and this is also consistent with the notion that IRP1 may not be important in the fetal liver at this stage.

The present study also determined the impact of the reduction in liver iron stores on fetal haematopoiesis. The findings that hemoglobin levels and erythroid differentiation were reduced in the absence of any change in fetal serum iron levels and even when loss of HAMP-responsiveness was confined to hepatocytes, are consistent with a paracrine role for hepatocytes in supporting hematopoiesis in the fetal liver. The current consensus is that erythroid progenitors acquire iron from nurse macrophages (39). One possibility is that fetal hepatocytes support hematopoiesis indirectly by supplying iron to these nurse macrophages. Another possibility is that fetal hepatocytes supply iron directly to erythroid progenitors. In the future, it would be important to establish whether hepatocyte iron stores are transferred to erythroid progenitors directly or indirectly and to identify the form(s) (transferrin, ferritin, heme) in which this iron transferred.

In conclusion, this study demonstrates that build-up of hepatic iron stores in late gestation requires the autocrine action of the HAMP/FPN axis in fetal hepatocytes. Formal interrogation of the roles of the HAMP/FPN and of the IRP axes in the placenta depends on the development of genetic tools that can target specific cell populations within the placenta without affecting iron control in the fetus or the mother.

Acknowledgments

This work was supported by a Medical Research Council project Grant (MR/L010054/1) awarded to S L-L and PAR. S L-L was the recipient of a British Heart Foundation Intermediate Basic Science Postdoctoral Fellowship (FS/12/63/29895).

Author Contributions

SL-L and PAR conceived study and sought funding; LK, GM, MW and SL-L collected data and analysed results; SL-L drafted manuscript; all authors were involved in reviewing and revising the manuscript.

Conflict of Interest

The authors declare no conflicts of interest.

REFERENCES

1. Hernandez-Martinez C, Canals J, Aranda N, Ribot B, Escribano J, Arijia V. Effects of iron deficiency on neonatal behavior at different stages of pregnancy. *Early human development*. 2011;87:165-169

2. Beard J. Recent evidence from human and animal studies regarding iron status and infant development. *The Journal of nutrition*. 2007;137:524S-530S
3. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T. Long-lasting neural and behavioral effects of iron deficiency in infancy. *Nutrition reviews*. 2006;64:S34-43; discussion S72-91
4. Pinero DJ, Li NQ, Connor JR, Beard JL. Variations in dietary iron alter brain iron metabolism in developing rats. *The Journal of nutrition*. 2000;130:254-263
5. Shafir T, Angulo-Barroso R, Jing Y, Angelilli ML, Jacobson SW, Lozoff B. Iron deficiency and infant motor development. *Early human development*. 2008;84:479-485
6. Hirata M, Kusakawa I, Ohde S, Yamanaka M, Yoda H. Risk factors of infant anemia in the perinatal period. *Pediatrics International*. 2017; 59:447-451
7. Freeman V, Mulder J, Van't Hof M, Hoey H, Gibney M. A longitudinal study of iron status in children at 12, 24 and 36 months. *Public Health Nutrition*. 1998, 1:93-100.
8. Grantham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. *The Journal of nutrition*. 2001;131:649S-666S; discussion 666S-668S
9. Lozoff B, Brittenham GM, Viteri FE, Wolf AW, Urrutia JJ. Developmental deficits in iron-deficient infants: Effects of age and severity of iron lack. *The Journal of pediatrics*. 1982;101:948-952
10. Lozoff B, Brittenham GM, Viteri FE, Wolf AW, Urrutia JJ. The effects of short-term oral iron therapy on developmental deficits in iron-deficient anemic infants. *The Journal of pediatrics*. 1982;100:351-357
11. Walter T, De Andraca I, Chadud P, Perales CG. Iron deficiency anemia: Adverse effects on infant psychomotor development. *Pediatrics*. 1989;84:7-17
12. Aukett MA, Parks YA, Scott PH, Wharton BA. Treatment with iron increases weight gain and psychomotor development. *Archives of disease in childhood*. 1986;61:849-857
13. Lozoff B, Brittenham GM, Wolf AW, McClish DK, Kuhnert PM, Jimenez E, Jimenez R, Mora LA, Gomez I, Krauskopf D. Iron deficiency anemia and iron therapy effects on infant developmental test performance. *Pediatrics*. 1987;79:981-995
14. Walter T, Pino P, Pizarro F, Lozoff B. Prevention of iron-deficiency anemia: Comparison of high- and low-iron formulas in term healthy infants after six months of life. *The Journal of pediatrics*. 1998;132:635-640
15. Idjradinata P, Pollitt E. Reversal of developmental delays in iron-deficient anaemic infants treated with iron. *Lancet*. 1993;341:1-4

16. Leong WI, Bowlus CL, Tallkvist J, Lonnerdal B. Dmt1 and fpn1 expression during infancy: Developmental regulation of iron absorption. *American journal of physiology. Gastrointestinal and liver physiology*. 2003;285:G1153-1161
17. Collard KJ. Iron homeostasis in the neonate. *Pediatrics*. 2009;123:1208-1216
18. Dallman PR . Changing iron needs from birth through adolescence. In: Fomon SJ, Zlotkin S, eds .Nutritional anemias. New York: Vevey:Raven Press,1992; 29–36
19. Heath AL, Tuttle CR, Simons MS, Cleghorn CL, Parnell WR. Longitudinal study of diet and iron deficiency anaemia in infants during the first two years of life. *Asia Pacific journal of clinical nutrition*. 2002;11:251-257
20. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*. 2004; 306:2090-2093
21. Ganz T (2005) Cellular iron: Ferroportin is the only way out. *Cell Metab* 1:155-157
22. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. *Blood*. 2005; 106:3710-3717
23. Lakhal-Littleton S, Crosby A, Frise M, Mohammad G, Carr C, Loick P, Robbins P. Intracellular iron deficiency in pulmonary arterial smooth muscle cells induces pulmonary arterial hypertension in mice. *Proc Natl Acad Sci USA*. 2019;116 (26) 13122-13130.
24. Zumerle S, Mathieu JR, Delga S, Heinis M, Viatte L, Vaulont S, Peyssonnaud C. Targeted disruption of hepcidin in the liver recapitulates the hemochromatotic phenotype. *Blood*. 2014;123:3646-3650
25. Pigeon C, Ilyin G, Coursaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *The Journal of biological chemistry*. 2001; 276:7811-7819
26. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirtori M, Sawadogo M, Kahn A, Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. *Proc Natl Acad Sci U S A*. 2002;99(7):4596-601.
27. Willemetz A, Lenoir A, Deschemin JC, Lopez-Otin C, Ramsay AJ, Vaulont S, Nicolas G. Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis. *Blood*. 2014;124(3):441-4.
28. Balesaria S, Hanif, R, Salama M. F, Raja K, Bayele H. K., McArdle, H, and Srail, S. K. Fetal iron levels are regulated by maternal and fetal Hfe genotype and dietary iron. *Haematologica*. 2012; 97, 661-669
29. Ganz T. Heparin and iron regulation, 10 years later. *Blood*. 2011;117:4425-4433.

30. Sangkhae V, Fisher AL, Wong S, Koenig MD, Tussing-Humphreys L, Chu A, Lelic M, Ganz T, Nemeth E. Effects of maternal iron status on placental and fetal iron homeostasis. *The Journal of clinical investigation*. 2020;130:625-640
31. Koulis M, Pop R, Porpiglia E, Shearstone JR, Hidalgo D, Socolovsky M.(2011) Identification and analysis of mouse erythroid progenitors using the CD71/Ter119 flow-cytometric assay. *Journal of visualized experiments: JoVE*. 2011.
32. Tabbah SM, Buhimschi CS, Rodewald-Millen K, Pierson CR, Bhandari V, Samuels P, Buhimschi IA. Hepcidin, an iron regulatory hormone of innate immunity, is differentially expressed in premature fetuses with early-onset neonatal sepsis. *American journal of perinatology*. 2018; 35:865-872
33. Toldi G, Stenczer B, Molvarec A, Takats Z, Beko G, Rigo J, Jr., Vasarhelyi B. Hepcidin concentrations and iron homeostasis in preeclampsia. *Clinical chemistry and laboratory medicine*. 2010; 48:1423-1426
34. Cardaropoli S, Todros T, Nuzzo AM, Rolfo A. Maternal serum levels and placental expression of hepcidin in preeclampsia. *Pregnancy hypertension*. 2018;11:47-53
35. Dao MC, Sen S, Iyer C, Klebenov D, Meydani SN. Obesity during pregnancy and fetal iron status: Is hepcidin the link? *Journal of perinatology : official journal of the California Perinatal Association*. 2013; 33:177-181
36. Morin AM, Gatev E, McEwen LM, MacIsaac JL, Lin DTS, Koen N, Czamara D, Raikonen K, Zar HJ, Koenen K, Stein DJ, Kobor MS, Jones MJ. Maternal blood contamination of collected cord blood can be identified using DNA methylation at three CpGs. *Clinical epigenetics*. 2017; 9:75
37. Mao J, McKean DM, Warrier S, Corbin JG, Niswander L, Zohn IE. The iron exporter ferroportin 1 is essential for development of the mouse embryo, forebrain patterning and neural tube closure. *Development*. 2010;137:3079-3088
38. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC. The iron exporter ferroportin/slca40a1 is essential for iron homeostasis. *Cell metabolism* 2005; 1:191-200
39. Bessis MC, Breton-Gorius J. Iron metabolism in the bone marrow as seen by electron microscopy: a critical review. *Blood* 1962;19:635–63.
40. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. *Nat Chem Biol*. 2006; 2:406-414

Figure Legends

Figure 1: Fetal liver iron concentration and hepcidin expression increase in the third trimester.

A. Total iron concentration in fetal livers harvested at e13.5 (n=27) and e17.5 (n=28) and in maternal livers at e17.5 (n=5). **B.** Relative hamp mRNA expression in fetal livers harvested at e13.5 (n=6) and e17.5 (n=6) and in maternal livers at e17.5 (n=5). **C.** Correlation between relative hamp expression and total iron concentration in fetal livers at e17.5 (n=18). Values are shown as mean±S.E.M. P values are calculated using Student's t test. *r* is Pearson's correlation coefficient.

Figure 2: Ubiquitous loss of FPN responsiveness to hepcidin in the fetus reduces fetal

liver iron stores and hemoglobin. **A.** Liver iron concentration in *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=6, 5, respectively), day 0 (n=5, 5), week 1 (n=5, 4), week 4 (n=3, 3) and week 12 (n=3, 3) of age. P values are shown relative to *fpn*^{wt/wt} littermate controls at the respective timepoint. **B.** Representative images of DAB-enhanced Perls' iron stain in the livers of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5. **C.** Extrahepatic iron concentration in *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates measured as carcass iron at e17.5 (n=6, 11) and as splenic iron at day 0 (n=4, 6), week 1 (n=4, 4), week 4 (n=3, 3) and week 12 (n=3, 3) of age. P values are shown relative to *fpn*^{wt/wt} littermate controls at the respective timepoint. **D.** Hemoglobin concentration in *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=6, 7), day 0 (n=3, 5), week 1 (n=3, 5), week 4 (n=3, 3) and week 12 (n=3, 3) of age. P values are shown relative to *fpn*^{wt/wt} littermate controls at the respective timepoint. **E.** Representative dot plots of erythroid progenitors from livers of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5. **F.** Quantitation of erythroid progenitor populations R1-R5 from livers of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=5, 3). **G.** Placental iron concentration in *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n= 6, 11). **H.** Relative expression of *tfr1* and *dmt1* mRNA transcripts in placentae of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=3, 5). **I.** Iron concentration in the serum of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=5, 4). **J.** Representative images of FPN immunostaining in the placentae of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5. **K.** Western blot for FPN in the placentae of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5A. **L.** Representative images of FPN immunostaining in the livers of *fpn*^{wt/wt} animals and *fpn*^{wt/C326Y} littermates at e17.5. **M.** Western blot for FPN in the livers of

$fpn^{wt/wt}$ animals and $fpn^{wt/C326Y}$ littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5B. Values are shown as mean±S.E.M. *P* values are calculated using Student's *t* test.

Figure 3: Liver-specific loss of FPN responsiveness to hepcidin reduces fetal liver iron stores and hemoglobin.

A. Liver iron concentration in $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=3, 3, respectively), day 0 (n=3, 4), week 1 (n=4, 3), week 4 (n=4, 4) and week 12 (n=3, 3) of age. *P* values are shown relative to $fpnC326Y^{fl/fl}$ littermate controls at the respective timepoint. **B.** Representative images of DAB-enhanced Perls' iron stain in the livers of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5. **C.** Extra-hepatic iron concentration in $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates measured as carcass iron at e17.5 (n=3, 5) and as splenic iron at day 0 (n=3, 4), week 1 (n=4, 3), week 4 (n=4, 4) and week 12 (n=3, 3) of age. *P* values are shown relative to $fpnC326Y^{fl/fl}$ littermate controls at the respective timepoint. **D.** Hemoglobin concentration in $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=12, 6), day 0 (n=4, 3), week1 (n=4, 3), week 4 (n=4, 4) and week 12 (n=3, 3) of age. *P* values are shown relative to $fpnC326Y^{fl/fl}$ littermate controls at the respective timepoint. **E.** Representative dot plots of erythroid progenitors from livers of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5. **F.** Quantitation of erythroid progenitor populations R1-R5 from livers of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=5, 4). **G.** Placental iron concentration in $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=11, 6). **H.** Relative expression of *tfr1* and *dmt1* mRNA transcripts in placentae of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=3, 5). **I.** Iron concentration in the serum of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=11, 6). **J.** Representative images of FPN immunostaining in the placentae of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5. **K.** Western blot for FPN in the placentae of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5C. **L.** Representative images of FPN immunostaining in the livers of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5. **M.** Western blot for FPN in the livers of $fpnC326Y^{fl/fl}$ animals and $fpnC326Y^{fl/fl}$, Alb.Cre+ littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5D. Values are shown as mean±S.E.M. *P* values are calculated using Student's *t* test.

Figure 4: Liver-specific loss of hepcidin reduces fetal liver iron stores and hemoglobin.

A. Liver iron concentration in *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=4, 4, respectively), day 0 (n=4, 4), week 1 (n=4, 4), week 4 (n=4, 3) and week 12 (n=3, 3) of age. *P* values are shown relative to *hamp*^{fl/fl} littermate controls at the respective timepoint.

B. Representative images of DAB-enhanced Perls' iron stain in the livers of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5. **C.** Extra-hepatic iron concentration in *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates measured as carcass iron at e17.5 (n=4, 5) and as splenic iron at day 0 (n=4, 4), week 1 (n=4, 5), week 4 (n=3, 4) and week 12 (n=3, 3) of age. *P* values are shown relative to *hamp*^{fl/fl} littermate controls at the respective timepoint. **D.** Hemoglobin concentration in *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=5, 3), day 0 (n=4, 4), week 1 (n=3, 5), week 4 (n=4, 3) and week 12 (n=3, 3) of age. *P* values are shown relative to *hamp*^{fl/fl} littermate controls at the respective timepoint. **E.** Representative dot plots of erythroid progenitors from livers of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5. **F.** Quantitation of erythroid progenitor populations R1-R5 from livers of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=4, 4). **G.** Placental iron concentration in *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n= 5, 4). **H.** Relative expression of *tfr1* and *dmt1* mRNA transcripts in placentae of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=4, 4). **I.** Iron concentration in the serum of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=4, 4). **J.** Representative images of FPN immunostaining in the placentae of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5. **K.** Western blot for FPN in the placentae of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5E. **L.** Representative images of FPN immunostaining in the livers of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5. **M.** Western blot for FPN in the livers of *hamp*^{fl/fl} animals and *hamp*^{fl/fl}, Alb.Cre+ littermates at e17.5 (n=3, 3). Normalised intensities are shown in supplemental figure 5F. Values are shown as mean±S.E.M. *P* values are calculated using Student's *t* test.

Figure 1




Figure 2




Figure 3




Figure 4

